1 / 23

Keith Skubitz 1 , Princy Francis 2 , Amy Skubitz 1 , Xianghua Luo 1 , and Mef Nilbert 2,3

Use of gene expression to identify heterogeneity of metastatic behavior among high-grade pleomorphic soft tissue sarcomas. Keith Skubitz 1 , Princy Francis 2 , Amy Skubitz 1 , Xianghua Luo 1 , and Mef Nilbert 2,3 1 University of Minnesota, 2 Lund University, 3 Hvidovre Hospital.

takoda
Download Presentation

Keith Skubitz 1 , Princy Francis 2 , Amy Skubitz 1 , Xianghua Luo 1 , and Mef Nilbert 2,3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Use of gene expression to identify heterogeneity of metastatic behavior among high-grade pleomorphic soft tissue sarcomas Keith Skubitz1, Princy Francis2, Amy Skubitz1, Xianghua Luo1, and Mef Nilbert2,3 1University of Minnesota, 2Lund University, 3Hvidovre Hospital

  2. Sarcomas are heterogeneous • Heterogeneity of biological behavior exists even within histologic subtypes of sarcomas, complicating clinical care, clinical trials, and drug development.

  3. Example • Assume treatment A has no adverse effect • Assume benefit of treatment A is all or none in a certain percentage of patients

  4. Some biological behaviors that do not correlate well with morphology may be determined by gene expression patterns

  5. A common approach to identify prognostic factors is to search for differences in gene expression between 2 groups defined by an outcome (eg survival) • Requires defining 2 groups • Irrelevant genes may obscure important patterns • Different genes could be important in different subsets

  6. Alternatively, identification of subsets independent of clinical information could be useful • We used PCA with a variety of gene sets in an attempt to identify heterogeneity • Clear cell renal carcinoma (RCC) • Serrous ovarian carcinoma (OVCA) • Aggressive fibromatosis (AF)

  7. PCA with 604 probes up or down >/=5-fold in ccRCC vs normal kidney B

  8. PCA with probes from ubiquitylation in control of cell cycle pathway A

  9. Gene expression patterns that distinguished 2 subsets of RCC (RCC gene set), OVCA (OVCA gene set), and AF (AF gene set) were identified

  10. Question • Do the RCC-, OVCA-, and AF-gene sets identify subsets of high-grade pleomorphic STS?

  11. Samples • 73 Samples obtained from Lund University • 40 MFH • 20 LMS • 9 other high-grade pleomorphic STS

  12. Data • cDNA microarray slides with ~16,000 unique UniGene clusters • About 50% of the genes in the RCC-, OVCA-, and AF- gene sets were present in this data set

  13. Methods • Data were pooled to form a set of 234 genes present in at least one of the RCC-, OVCA-, or AF-gene sets • Hierarchical clustering using this gene set was performed

  14. Hierarchical Clustering

  15. Hierarchichal Clustering 1 2 3 4

  16. Important Caveats • Clustering pattern depends on composition of sample set • Many types of clustering and ways to modify data

  17. Conclusions • Analysis of a set of STS using a gene set derived from other tumor systems without regard to clinical data, identified differences in time to metastasis • Thus, an approach to subcategorizing samples before searching for variables that correlate with clinical behavior may be useful

  18. Conclusions • Although no confirmation of clinical relevance is available, stratifying patients entering trials by a similar approach could be useful, and would not result in loss of information

  19. Conclusions • Although no confirmation of clinical relevance is available, stratifying patients entering trials by a similar approach could be useful, and would not result in loss of information • Banked samples should be obtained for all STS patients entering clinical trials for later analysis

More Related